Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 9:15 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 9:15 a.m. EST. The management team will also engage in one-on-one meetings during the event, which runs from November 30 to December 2, 2021. A live webcast and an archived recording will be available on their website for 90 days post-event. Phathom focuses on developing treatments for gastrointestinal diseases, notably with vonoprazan, a potassium competitive acid blocker.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was +2.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate virtually in the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021 at 9:15 a.m. EST.
Members of Phathom’s management team will also participate in one-on-one meetings throughout the conference which runs from November 30 – December 2, 2021.
To access the live webcast and archived recording of the presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at http://www.phathompharma.com/ and follow the Company on LinkedIn and Twitter.
CONTACTS
Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com
Investor Contact:
Joe Hand
1-877-742-8466
ir@phathompharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.